Advertisement
Dr. Henderson's presentation will be webcast live and will be accessiblefrom the Investor Information page of the Company's Website athttp://investors.keryx.com. An archived version of the webcast will beavailable following the conclusion of the live presentation.
Advertisement
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, developmentand commercialization of medically important, novel pharmaceutical productsfor the treatment of life-threatening diseases, including diabetes and cancer.Keryx's lead compound under development is Sulonex(TM) (sulodexide),previously referred to as KRX-101, a first-in-class, oral heparinoid compoundfor the treatment of diabetic nephropathy, a life-threatening kidney diseasecaused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinicalprogram under a Special Protocol Assessment with the Food & DrugAdministration. Additionally, Keryx is developing Zerenex(TM), an oral,inorganic, iron-based compound that has the capacity to bind phosphate andform non-absorbable complexes. Zerenex is currently in Phase II clinicaldevelopment for the treatment of hyperphosphatemia (elevated serum phosphorouslevels) in patients with end-stage renal disease. Keryx is also developingclinical-stage oncology compounds, including KRX-0401 (perifosine), a novel,first-in-class, oral modulator of Akt, a pathway associated with tumorsurvival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types.Keryx also has an active in-licensing and acquisition program designed toidentify and acquire additional drug candidates. Keryx is headquartered in NewYork City.KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965
SOURCE Keryx Biopharmaceuticals, Inc.
